首页 > 抗体蛋白 > 抗体
PerCP anti-human CD3 Antibody
产品名称:
PerCP anti-human CD3 Antibody
产品类别:
抗体
产品编号:
300427
产品应用:
300427
[价格]
规格 价格 库存
25tests ¥ 2142 1

产品详情

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The CD3 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

* PerCP has a maximum absorption of 482 nm and a maximum emission of 675 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections4,6,7 and formalin-fixed paraffin-embedded sections11, immunoprecipitation1, activation of T cells2,3,5, Western blotting9, and spatial biology (IBEX)16,17. The LEAF? purified antibody (Endotoxin < 0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 300413, 300414, and 300432). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 300437, 300438, 300465, 300466, 300473, 300474) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin < 0.01 EU/?g).

Application References

(PubMed link indicates BioLegend citation)
  1. Salmeron A, et al. 1991. J. Immunol. 147:3047. (IP)
  2. Graves J, et al. 1991. J. Immunol. 146:2102. (Activ)
  3. Lafont V, et al. 2000. J. Biol. Chem. 275:19282. (Activ)
  4. Ryschich E, et al. 2003. Tissue Antigens 62:48. (IHC)
  5. Thompson AG, et al. 2004. J. Immunol. 173:1671. (Activ)
  6. Sakkas LI, et al. 1998. Clin. Diagn. Lab. Immun. 5:430. (IHC)
  7. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
  8. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  9. Van Dongen JJM, et al. 1988. Blood 71:603. (WB)
  10. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  11. Pollard, K. et al. 1987. J. Histochem. Cytochem. 35:1329. (IHC)
  12. Luckashenak N, et al. 2013. J. Immunol. 190:27. PubMed
  13. Laurent AJ, et al. 2014. PLoS One. 9:103683. PubMed
  14. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  15. Stoeckius M, et al. 2017. Nat. Methods. 14:865-868. (PG)
  16. Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
  17. Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed
Product Citations
  1. Wenthe J, et al. 2021. Cancer Immunology Immunotherapy. . PubMed
  2. Zhou J, et al. 2020. Oncol Lett. 1.336111111. PubMed
  3. Ahmed R et al. 2019. Cell. 177(6):1583-1599 . PubMed
  4. Rother S, et al. 2015. PLoS One. 10: 0135682. PubMed
  5. Barra NG, et al. 2017. J Cancer Prev. 1.097222222. PubMed
  6. D, et al. 2016. Tuberculosis. 95: 470-475. PubMed
  7. Hydes T, et al. 2017. Immun Inflamm Dis. 10.1002/iid3.190. PubMed
  8. Dean JW, et al. 2020. J Autoimmun. 108:102417. PubMed
  9. Gerstner S, et al. 2016. J Leukoc Biol. 100(6):1297-1310. PubMed
  10. Alexander T, et al. 2013. Ann Rheum Dis. 72:1549. PubMed
  11. Livingston K, et al. 2013. J Immunol Methods. 390:18. PubMed
  12. Bastiaens G, et al. 2016. Am J Trop Med Hyg. 94: 663 - 673. PubMed
  13. Urlaub D, et al. 2017. J Immunol. 198:1944. PubMed
  14. Veerdonk F, et al. 2010. J Leukoc Biol. 88:227. PubMed
  15. Teirlinck A, et al. 2011. PLoS One. 7:e1002389. PubMed
  16. Bigler M, et al. 2015. PLoS One. 10: 0145635. PubMed
  17. Cooper GE, et al. 2018. Front Immunol. 9:1671. PubMed
  18. Zuccato C, et al. 2022. Ther Adv Hematol. 13:20406207221100648. PubMed
  19. Wendisch D, et al. 2021. Cell. 184:6243. PubMed
  20. Meermeier E, et al. 2016. Nat Commun. 7:12506. PubMed
  21. Tognarelli S, et al. 2018. Front Immunol. 9:2743. PubMed
  22. Salvany‐Celades M et al. 2019. Cell Rep. 27(9):2537-2547 . PubMed
  23. Wang W, et al. 2019. Cell Rep. 28:486. PubMed
  24. Leng T, et al. 2019. Cell Rep. 28:3077. PubMed
  25. Linder A, et al. 2020. EMBO J. 39:e105071. PubMed
  26. Fisher JG, et al. 2021. Front Oncol. 11:785635. PubMed
  27. FitzPatrick MEB, et al. 2021. Cell Rep. 34:108661. PubMed
  28. Bartholomaeus P, et al. 2014. J Immunol. 192:2091. PubMed
  29. Reitinger C, et al. 2022. Front Immunol. 13:970290. PubMed
  30. Dannenmann S, et al. 2013. Oncoimmunology. 2:23562. PubMed
  31. Obiero J, et al. 2015. Infect Immun . 83:2185. PubMed
  32. Groen B, et al. 2015. Sci Rep. 5: 13618. PubMed
  33. Kim N, et al. 2020. Nat Commun. 2.045138889. PubMed
  34. Sananez I, et al. 2021. EBioMedicine. 72:103615. PubMed
RRID
AB_893300 (BioLegend Cat. No. 300427) AB_893298 (BioLegend Cat. No. 300428)

Antigen Details

Structure
Ig superfamily, with the subunits of CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) forms CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
3. Lanier L, et al. 1986. J. Immunol. 137:2501-2507.

Gene ID
916 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线